Evidence map›Paper›PMID 35614383›Full record

ArticleThe journal of headache and pain2022

Characterization of erenumab and rimegepant on calcitonin gene-related peptide induced responses in Xenopus Laevis oocytes expressing the calcitonin gene-related peptide receptor and the amylin-1 receptor.

Sanne Hage La Cour, Kiki Juhler, Lisette J A Kogelman, Jes Olesen, Dan Arne Klærke, David Møbjerg Kristensen, Inger Jansen-Olesen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of headache and pain, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 17 citations in OpenAlex.

  1. Long-term real-world effectiveness and safety of fremanezumab in 1140 patients with migraine and at least 6 months of treatment: third interim analysis of the pan-European PEARL study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Trial
  2. Trial
  3. Observational
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Future targets for migraine treatment beyond CGRP.The journal of headache and pain · 2023
    Review
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Sanne Hage La CourDanish Headache Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Kiki JuhlerDanish Headache Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Lisette J A KogelmanDanish Headache Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Jes OlesenDanish Headache Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Dan Arne KlærkeDepartment of Veterinary and Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Frederiksberg C, Denmark.
David Møbjerg KristensenDanish Headache Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Inger Jansen-OlesenDanish Headache Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. inger.jansen-olesen@regionh.dk.
University of Copenhagen · DKRigshospitalet · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe clinical use of calcitonin gene-related peptide receptor (CGRP-R) antagonists and monoclonal antibodies against CGRP and CGRP-R has offered new treatment possibilities for migraine patients. CGRP activates both the CGRP-R and structurally related amylin 1 receptor (AMY

methodsThe effect of CGRP and two CGRP-R antagonists were examined in Xenopus laevis oocytes expressing human CGRP-R, human AMY

resultsCGRP administered to receptor expressing oocytes induced a concentration-dependent increase in current with the order of potency CGRP-R> > AMY

conclusionOur results demonstrate that erenumab and rimegepant are potent antagonists of CGRP-R and AMY

Indexed as

Antibodies, Monoclonal, HumanizedCalcitonin Gene-Related PeptidePiperidinesPyridinesReceptors, Calcitonin Gene-Related PeptideReceptors, Islet Amyloid PolypeptideAnimalsIslet Amyloid PolypeptideOocytesReceptors, CalcitoninXenopus laevisAntibodies, Monoclonal, HumanizedCalcitonin Gene-Related PeptideerenumabIslet Amyloid PolypeptidePiperidinesPyridinesReceptors, CalcitoninReceptors, Calcitonin Gene-Related PeptideReceptors, Islet Amyloid Polypeptiderimegepant sulfateAmylinAmylin receptorCGRPCLRCTRMigraineRAMP1Xenopus Laevis oocytes

Identifiers

PMID35614383
PMCPMC9134599
OpenAlexW4281565985

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.